Company intelligence / Profile preview

Orbits Oncology

Ownership: Private
Development stage: Preclinical

Overview

Orbits Oncology has developed an AI-driven digital platform that analyzes patient-derived tumor organoids to predict real-world patient responses to cancer therapies. The technology aims to bridge the gap between preclinical research and clinical outcomes by providing high-resolution, automated metrics from live-cell imaging of 3D models. No direct clinical results as the company is a technology provider rather than a drug developer.

Therapeutic areas: Oncology
Modalities: AI-powered Organoid AnalysisDrug Screening Support
Industry: Drug Discovery Services

Partnerships

Merck Digital Sciences Studio/MDSS program participantCollaborations with biopharma companies for drug screening assays

Beyond the preview

Go deeper on Orbits Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orbits Oncology.

Explore the full profile